Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
Luc-Matthieu Fornecker*, Julien Lazarovici, Igor Aurer, René-Olivier Casasnovas, Anne-Claire Gac, Christophe Bonnet, Krimo Bouabdallah, Pierre Feugier, Lena Specht, Lysiane Molina, Mohamed Touati, Cécile Borel, Aspasia Stamatoullas, Emmanuelle Nicolas-Virelizier, Laurent Pascal, Pieternella Lugtenburg, Nicola Di Renzo, Thierry Vander Borght, Alexandra Traverse-Glehen, Peggy DartiguesMartin Hutchings, Annibale Versari, Michel Meignan, Massimo Federico, Marc André, LYSA-FIL-EORTC Intergroup
Dyk ned i forskningsemnerne om 'Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial'. Sammen danner de et unikt fingeraftryk.